PeptMentor
CalculatorsHow we source
PeptMentor
PeptMentor
Peptides
Eloralintide
Retatrutide
GHK-Cu
Pinealon
KPV
KLOW
All peptides
Compared
Eloralintide vs cagrilintide
Eloralintide vs retatrutide
Retatrutide vs tirzepatide
Guides and tools
Bac water for peptides
How to reconstitute peptides
Peptide reconstitution calculator
All guides
About
How we source
About
Editorial policy
Open the peptide calculator
PeptMentor

Plain answers about peptides and GLP-1 medicines. Every figure links to its source and says what kind of study it came from.

No dose advice. No sponsors, sellers or affiliate codes.

Peptides

  • Eloralintide
  • GHK-Cu
  • KLOW
  • KPV
  • Pinealon
  • Retatrutide
  • All peptides

Compare

  • Eloralintide vs cagrilintide
  • Eloralintide vs retatrutide
  • Retatrutide vs tirzepatide

Guides and tools

  • Peptide reconstitution calculator
  • Bac water for peptides
  • How to reconstitute peptides
  • All guides

About us

  • About
  • How we check facts
  • Editorial policy
  • Sources
  • Contact
© 2026 PeptMentor LLC. For information only, not medical advice. In an emergency call 911.
Medical disclaimerTermsPrivacyConsumer health data
  1. /Home
  2. /Blog
  3. /Eloralintide vs cagrilintide
Comparison

Eloralintide vs cagrilintide: trials and status

Eloralintide vs cagrilintide is a comparison of two weekly amylin-pathway injections. Eloralintide is made by Eli Lilly and cagrilintide by Novo Nordisk.

Illustration of two peptide chains on one cell: one docking into one receptor, the other into two
Illustration
Cross-trial: no head-to-headNeither approved alone

Facts checked 2026-11-17 · by PeptMentor Team · How we source

On this page
The short answerSide by sideHow they differ: receptors and half-lifeWeight-loss resultsSide effectsCan either be taken with tirzepatide or retatrutide?All trial armsClaims we checkedApproval status and timelineHow to read these numbersEloralintide vs cagrilintide: questions people askSources

The short answer

Both are once-weekly amylin-pathway injections, and neither is approved alone. Eloralintide (Lilly) prefers one amylin receptor, AMY1R, 12-fold over the calcitonin receptor in cell tests[1]. Cagrilintide (Novo Nordisk) acts on amylin and calcitonin receptors without that preference[2]. Alone, eloralintide reached up to −20.1% body weight at 48 weeks in phase 2[3]; cagrilintide alone reached −11.5% at 68 weeks in a phase 3 arm (as cited by Briere 2025[1]). No head-to-head human trial exists (ClinicalTrials.gov, searched 2026-11-17).

Eloralintide
CellAnimalSmall humanHuman randomised trialApproved

Best evidence: human randomised trial

Eloralintide: best evidence is a human RCT (phase 2, 48 weeks). Phase 3 is running.

Cagrilintide
CellAnimalSmall humanHuman randomised trialApproved

Best evidence: human randomised trial

Cagrilintide: best evidence is human RCTs (phase 2, and a phase 3 arm inside REDEFINE 1). Not approved on its own.

Neither is approved on its own, and no trial has tested one against the other. This page puts the published results side by side, says which trial each number came from, and shows where each drug stands with regulators.

Side by side

FeatureEloralintideCagrilintide
DeveloperEli Lilly (code LY3841136)Novo Nordisk
How it worksSelective amylin receptor agonist: AMY1R 12-fold over the calcitonin receptor in cells[1]Non-selective amylin and calcitonin receptor agonist (review)[2]
StatusPhase 3 (ENLIGHTEN, 8 trials registered); not approved anywhereNot approved alone. Its combination with semaglutide (CagriSema) was submitted to FDA on 2025-12-18 (Novo Nordisk US press release); no FDA decision found as of 2026-11-17
Latest phase with resultsPhase 2[3]Phase 3 arm in REDEFINE 1 (cited in[1])
Weight change, aloneUp to −20.1% at 48 weeks vs −0.4% placebo (efficacy estimand)[3]−6.0% to −10.8% at 26 weeks vs −3.0% placebo[4]; −11.5% at 68 weeks in REDEFINE 1 (cited in[1])
Half-life12.9–15.3 days, single dose[1]6.6–8.1 days, as cited in the same paper[1]
Nausea in phase 211–64% by arm vs 14% placebo[3]20–47% by arm vs 18% placebo[4]
Signature side effectFatigue, 0–46% by arm vs 12% placebo[3]No data on this site yet
Combination productEloraTZP (with tirzepatide): phase 2b, up to −23.3% at 48 weeks (Lilly press release, 2026-09-30)[5]CagriSema (with semaglutide): −20.4% vs −3.0% at 68 weeks[6]

Cross-trial table. The trials differ in length (26, 48 and 68 weeks), population and estimand, so the numbers in one row are not a head-to-head result.

How they differ: receptors and half-life

Amylin is a hormone released with insulin. Drugs that copy it slow stomach emptying and signal fullness. Both drugs act on this pathway, which is why neither is a GLP-1 drug.

The difference is which receptors they switch on. In human cell tests, eloralintide activated the AMY1 receptor 12-fold more strongly than the calcitonin receptor and 11-fold more strongly than AMY3R. In rats the pattern was different (cell data)[1]. Cagrilintide acts on amylin and calcitonin receptors alike[2]. We have not found cagrilintide figures from the same cell test, so the two cannot be put on one scale.

Separate trials: not a head-to-head comparison

Half-life after a single dose (range in days)

Scale: 0–15.3 days

Eloralintide12.9–15.3 days
Cagrilintide6.6–8.1 days

Eloralintide from its phase 1 study; cagrilintide as cited in the same paper[1]. How long a drug stays in the body. This is not a schedule.

Names that get mixed up: CagriSema is cagrilintide plus semaglutide in one product. EloraTZP is eloralintide plus tirzepatide. Eloralintide's code name is LY3841136.

Weight-loss results

TrialDrugWeeksWeight change (top arm)PlaceboSource
Phase 2 (Human RCT)Eloralintide alone48−20.1% (efficacy)−0.4%[3]
Phase 2 (Human RCT)Cagrilintide alone26−6.0% to −10.8% across arms−3.0%[4]
REDEFINE 1 (Human RCT)Cagrilintide alone68−11.5%no data hereCited in[1]
Phase 2b, type 2 diabetes (Company press release)EloraTZP48−23.3% (efficacy)−3.0%Lilly, 2026-09-30[5]
REDEFINE 1 (Human RCT)CagriSema68−20.4% (treatment-policy)−3.0%[6]

Each drug alone and in its combination product. Different trials, lengths and estimands: read each row on its own.

Two cautions. The EloraTZP figure is from a press release and was in people with type 2 diabetes, who usually lose less weight than people without it. And comparing eloralintide alone with CagriSema mixes a single drug with a combination, which several ranking pages do.

Side effects

In the eloralintide 9 mg arm, nausea was reported by 33% and fatigue by 43%, against 14% and 12% on placebo (human randomised trial)[3]. See all trial arms below for each dose tested.

Cagrilintide's phase 2 trial reported nausea in 20–47% of people across arms, against 18% on placebo[4]. In REDEFINE 1, gastrointestinal side effects were reported by 79.6% on CagriSema and 39.9% on placebo[6].

Animal data only: "less nausea"
In a Lilly-run study in lean rats, eloralintide caused less conditioned taste avoidance (a rat stand-in for feeling unwell) than cagrilintide, p < 0.05[1]. No human trial has compared how well people tolerate the two.

Can either be taken with tirzepatide or retatrutide?

Only the combinations below have been tested in trials. EloraTZP pairs eloralintide with tirzepatide: phase 2b has reported (Lilly press release, 2026-09-30)[5] and two phase 3 trials are registered[7][8]. CagriSema pairs cagrilintide with semaglutide[6].

What no trial has tested
Eloralintide against cagrilintide. Eloralintide or cagrilintide with retatrutide. How well people tolerate one compared with the other. Eloralintide's effect on body composition.

ClinicalTrials.gov, searched 2026-11-17

More on EloraTZP is on the eloralintide page. For the other Lilly comparison, see eloralintide vs retatrutide.

All trial arms

Eloralintide weight loss, nausea and fatigue by arm.
Eloralintide phase 2: weight lost at 48 weeks (% of body weight) Eloralintide arm Placebo

Scale: 0–20.1%

1 mg9.5% vs 0.4%
3 mg12.4% vs 0.4%
6 mg17.6% vs 0.4%
9 mg20.1% vs 0.4%
6→9 mg19.9% vs 0.4%
3→6→9 mg16.4% vs 0.4%

Published trial arms, efficacy estimand (as if everyone stayed on treatment). n = 263 adults with obesity or overweight, no type 2 diabetes[3]. Not a dose recommendation.

Eloralintide phase 2: nausea by arm (% of participants) Eloralintide arm Placebo

Scale: 0–70%

1 mg11% vs 14%
3 mg13% vs 14%
6 mg64% vs 14%
9 mg33% vs 14%
6→9 mg54% vs 14%
3→6→9 mg25% vs 14%

From the Lancet abstract[3], which rounds to whole numbers.

Eloralintide phase 2: fatigue by arm (% of participants) Eloralintide arm Placebo

Scale: 0–70%

1 mg0% vs 12%
3 mg13% vs 12%
6 mg29% vs 12%
9 mg43% vs 12%
6→9 mg46% vs 12%
3→6→9 mg21% vs 12%

Same trial[3].

Claims we checked

ClaimVerdictWhat the source says
Cagrilintide alone reached "mid-teens" weight loss in REDEFINE 1 (a ranking comparison page)Wrong−11.5% at 68 weeks, as cited in[1]
Eloralintide causes less nausea than cagrilintideNo human sourceOnly a Lilly rat study on taste avoidance[1]
Eloralintide will replace cagrilintideNo sourceNo trial compares them; neither is approved alone

Approval status and timeline

  1. 2021

    Cagrilintide phase 2 published: −6.0% to −10.8% at 26 weeks.

    Lau et al., Lancet 2021[4] Human randomised trial
  2. 2025

    REDEFINE 1 (CagriSema) published in NEJM: −20.4% vs −3.0% at 68 weeks.

    Garvey et al., NEJM 2025[6] Human randomised trial
  3. 2025-11-06

    Eloralintide phase 2 published online in the Lancet.

    Billings et al., Lancet 2025[3] Human randomised trial
  4. 2025-12-15

    First eloralintide phase 3 trial (ENLIGHTEN-2) starts.

    ClinicalTrials.gov[9] Trial registry
  5. 2026-09-30

    EloraTZP phase 2b results announced; not yet peer-reviewed.

    Lilly press release[5] Company press release
  6. 2026-10-01

    FDA states cagrilintide cannot be used in compounding under federal law.

    FDA statement on unapproved GLP-1 drugs[10] Regulator
  7. 2028-01 (est.)

    Earliest estimated primary completion of an eloralintide phase 3 trial (ENLIGHTEN-2).

    ClinicalTrials.gov[9] Trial registry

CagriSema was submitted to FDA on 2025-12-18 (Novo Nordisk US press release). Novo guided a decision in the fourth quarter of 2026. We found no approval or rejection as of 2026-11-17 and will update this page when one is published.

How to read these numbers

Cross-trial figures are not head-to-head
Every comparison on this page sets results from separate trials next to each other. The trials differ in length, population and estimand (whether people who stopped treatment are counted). Only a trial that randomises people to both drugs can say which works better, and none exists.

Eloralintide vs cagrilintide: questions people ask

Direct answers to what people search for. Bracketed numbers point to the sources at the end; the sections above have the detail.

Is eloralintide better than cagrilintide?

No trial has compared them. In separate trials, eloralintide alone reached up to −20.1% at 48 weeks[3] and cagrilintide alone −11.5% at 68 weeks (cited in[1]), with different designs and estimands.

Is eloralintide a GLP-1?

No. It is an amylin receptor agonist that prefers the AMY1 receptor[1]. Lilly is testing it with tirzepatide, which does act on GLP-1 receptors.

Is cagrilintide the same as CagriSema?

No. CagriSema is cagrilintide combined with semaglutide. In REDEFINE 1 it reached −20.4% at 68 weeks vs −3.0% on placebo[6].

Which causes less nausea?

There is no human comparison. Nausea in phase 2 was 11–64% by arm for eloralintide vs 14% placebo, and 20–47% for cagrilintide vs 18% placebo, in different trials. The only direct comparison is a rat study.

Can I take cagrilintide and tirzepatide together?

No trial has tested cagrilintide with tirzepatide. The tested combinations are cagrilintide with semaglutide (CagriSema) and eloralintide with tirzepatide (EloraTZP).

Is either FDA approved?

No. Eloralintide is in phase 3. Cagrilintide is not approved alone, and FDA says it cannot be used in compounding[10]. CagriSema awaits an FDA decision.

When will eloralintide be available?

No date has been announced. The earliest phase 3 trial is estimated to reach primary completion in January 2028[9], and a filing would come after that.

Will eloralintide replace cagrilintide?

There is no source for that. Both are still investigational on their own, and no trial compares them.

Sources

  1. 1.Briere et al. Eloralintide discovery and phase 1. Mol Metab 2025. PMID 41109426 Small human study
  2. 2.Bailey 2026, review
  3. 3.Billings et al. Eloralintide phase 2, 48 weeks. Lancet 2025. PMID 41207310 Human randomised trial
  4. 4.Lau et al. Cagrilintide phase 2. Lancet 2021. PMID 34798060 Human randomised trial
  5. 5.EloraTZP phase 2b trial record, NCT06603571 (results via Lilly press release, 2026-09-30) Company press release
  6. 6.Garvey et al. REDEFINE 1 (CagriSema). NEJM 2025. PMID 40544433 Human randomised trial
  7. 7.AMPLIFY-1 trial record, NCT07881432 Trial registry
  8. 8.AMPLIFY-2 trial record, NCT07881458 Trial registry
  9. 9.ENLIGHTEN-2 trial record, NCT07282600 Trial registry
  10. 10.FDA: concerns with unapproved GLP-1 drugs used for weight loss (2026-10-01) Regulator
On this pageThe short answerSide by sideHow they differ: receptors and half-lifeWeight-loss resultsSide effectsCan either be taken with tirzepatide or retatrutide?All trial armsClaims we checkedApproval status and timelineHow to read these numbersEloralintide vs cagrilintide: questions people askSources